🏆 Deal of the Week · CW 32/2022
Vector Biopharma raised USD 30 million in a Series A round; the company's valuation was not disclosed. The round was led exclusively by Versant Ventures. The financing was announced in August 2022 and recognized by Venionaire DealMatrix as Deal of the Week for KW 32/2022.
Vector Biopharma — key deal facts
| Company | Vector Biopharma |
| Founded | 2021 |
| Headquarters | Basel, Switzerland |
| Amount raised | USD 30M |
| Valuation | Valuation Remains Undisclosed |
| Round | Series A |
| Investors | Versant Ventures (https://www.versantventures.com/) |
| Sectors | Life Science |
Who invested in Vector Biopharma?
Versant Ventures is the sole disclosed investor in this Series A. Versant is a specialist life-science venture capital firm with a track record of backing early-stage biotechnology platforms, making it a strategically aligned partner for Vector Biopharma's gene delivery ambitions. The concentration of capital from a single, sector-focused lead investor reflects a conviction-driven syndicate structure common in deep-technology biotech rounds.
What does Vector Biopharma do?
Vector Biopharma AG was founded in 2021 and is headquartered in Basel, Switzerland. The company develops a precision gene delivery platform based on engineered, non-viral virus-like particles designed to address key limitations of conventional gene therapy vectors, including restricted cargo size, immunogenicity, and poor tissue specificity. Its proprietary capsid shielding technology enables payloads of up to 36 kilobases of DNA, supporting therapeutic programmes in immuno-oncology, cellular therapies, and genome editing. The company was co-founded by CEO Lorenz Mayr, Ph.D., and scientific founder Professor Andreas Plückthun of the University of Zurich.
Vector Biopharma valuation & multiples
No existing multiples analysis was provided for this deal. As a private, pre-revenue Series A company, public EV/Sales or EV/EBITDA benchmarks are not directly applicable; comparable listed gene therapy and non-viral delivery peers can, however, serve as a reference frame for relative valuation. For sector-level transaction multiples in Life Sciences, readers can consult the relevant sector multiples pages on DealMatrix.
Explore the benchmarks: Series A.
Frequently asked questions
How much did Vector Biopharma raise in its Series A?
Vector Biopharma raised USD 30 million in its Series A round, announced in August 2022.
What is Vector Biopharma's valuation?
Vector Biopharma's valuation was not disclosed in connection with this Series A financing.
Who invested in Vector Biopharma?
Versant Ventures is the sole disclosed investor in Vector Biopharma's Series A round.
When was Vector Biopharma founded and where is it based?
Vector Biopharma was founded in 2021 and is headquartered in Basel, Switzerland.
Source: original announcement — read the full report.